2015
Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets
Sehgal K, Das R, Zhang L, Verma R, Deng Y, Kocoglu M, Vasquez J, Koduru S, Ren Y, Wang M, Couto S, Breider M, Hansel D, Seropian S, Cooper D, Thakurta A, Yao X, Dhodapkar KM, Dhodapkar MV. Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. Blood 2015, 125: 4042-4051. PMID: 25869284, PMCID: PMC4481593, DOI: 10.1182/blood-2014-11-611426.Peer-Reviewed Original ResearchConceptsImmune activationAntitumor effectsNK cellsT cellsMore frequent adverse eventsClinical antitumor effectsFrequent adverse eventsNatural killer cellsIntermittent dosing strategyDirect antitumor effectsExpression of cytokinesT cell activationGreater tumor reductionPomalidomide/Coinhibitory receptorsAdverse eventsClinical responseOverall survivalKiller cellsPharmacodynamic effectsImmunomodulatory effectsMultiple myelomaTumor reductionIntermittent dosingPharmacodynamic analysis
2000
Isolation and flow cytometric analysis of T‐cell‐depleted CD34+ PBPCs
Debelak J, Shlomchik M, Snyder E, Cooper D, Seropian S, McGuirk J, Smith B, Krause D. Isolation and flow cytometric analysis of T‐cell‐depleted CD34+ PBPCs. Transfusion 2000, 40: 1475-1481. PMID: 11134567, DOI: 10.1046/j.1537-2995.2000.40121475.x.Peer-Reviewed Original Research